[{"orgOrder":0,"company":"Innovaderm","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Innovaderm \/ Innovaderm","highestDevelopmentStatusID":"15","companyTruncated":"Innovaderm \/ Innovaderm"},{"orgOrder":0,"company":"Innovaderm","sponsor":"InflaRx","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovaderm \/ Innovaderm","highestDevelopmentStatusID":"10","companyTruncated":"Innovaderm \/ Innovaderm"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovaderm \/ Janssen Ortho LLC","highestDevelopmentStatusID":"10","companyTruncated":"Innovaderm \/ Janssen Ortho LLC"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Aquinox Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"AQX-1125","moa":"Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Innovaderm \/ Innovaderm","highestDevelopmentStatusID":"8","companyTruncated":"Innovaderm \/ Innovaderm"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovaderm \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Aralez Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Acitretin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Innovaderm \/ Aralez Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Innovaderm \/ Aralez Pharmaceuticals"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Vitamin E","moa":"SEC14-like protein 4; SEC14-like protein 3; SEC14-like protein 2; Nuclear receptor subfamily 1 group I member 2; Protein kinase C beta type; Polyunsaturated fatty acid 5-lipoxygenase; Protein kinase C alpha type; Diacylglycerol kinase alpha; Serine\/threonine-protein phosphatase 2A catalytic subunit beta isoform; Serine\/threonine-protein phosphatase 2A catalytic subunit alpha isoform","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Phase III","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Innovaderm \/ Merz Pharma"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BMX-010","moa":"Superoxide Radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Innovaderm \/ Innovaderm","highestDevelopmentStatusID":"8","companyTruncated":"Innovaderm \/ Innovaderm"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Abbott Laboratories | Montreal Heart Institute","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovaderm \/ Abbott Laboratories | Montreal Heart Institute","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Abbott Laboratories | Montreal Heart Institute"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Abbott Laboratories"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Abbott Laboratories"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Immunology","graph2":"Phase I","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Innovaderm \/ Innovaderm","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Innovaderm"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Escalier Biosciences BV","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ESR-114","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Innovaderm \/ Innovaderm","highestDevelopmentStatusID":"7","companyTruncated":"Innovaderm \/ Innovaderm"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Lipikar Balm AP","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Innovaderm","highestDevelopmentStatusID":"1","companyTruncated":"Innovaderm \/ Innovaderm"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"OpSCF","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Innovaderm","highestDevelopmentStatusID":"8","companyTruncated":"Innovaderm \/ Innovaderm"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Varicella Zoster Vaccine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Merck & Co"}]

Find Clinical Drug Pipeline Developments & Deals by Innovaderm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hand Dermatoses.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 28, 2024

                          Lead Product(s) : Abrocitinib

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Ruxolitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lupus Erythematosus, Discoid.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 15, 2024

                          Lead Product(s) : Ruxolitinib Phosphate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : OpSCF is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 26, 2023

                          Lead Product(s) : OpSCF

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Recipient : Opsidio, LLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Triamcinolone Acetonide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 06, 2023

                          Lead Product(s) : Triamcinolone Acetonide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 02, 2022

                          Lead Product(s) : Abrocitinib

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Bimekizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          August 12, 2022

                          Lead Product(s) : Bimekizumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : CIUSSS de l'Est-de-l'Île-de-Montréal

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : BMX-010 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 08, 2022

                          Lead Product(s) : BMX-010

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Recipient : BioMimetix JV

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist,is a non-steroidal topical that is a new chemical entity approved in the US for the topical treatment of plaque psoriasis in adults.

                          Product Name : Vtama

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 21, 2022

                          Lead Product(s) : Tapinarof

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Recipient : Dermavant Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Ruxolitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 05, 2021

                          Lead Product(s) : Ruxolitinib Phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Recipient : Incyte Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Vilobelimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pyoderma Gangrenosum.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          June 03, 2019

                          Lead Product(s) : Ifx-1

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Recipient : InflaRx

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank